Understanding Drug Interactions in Chronic Myeloid Leukemia Treatment
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia: PHARM-LMC Study
This study is testing how different treatments work together for people with Chronic Myeloid Leukemia who are taking Tyrosine Kinase Inhibitors to see if adjusting their medications can help them do better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Drugs / interventions | Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib |
| Locations | 1 site (Saint-Etienne) |
| Trial ID | NCT05130138 on ClinicalTrials.gov |
What this trial studies
This trial aims to identify and analyze concomitant treatments for patients with Chronic Myeloid Leukemia (CML) who are taking Tyrosine Kinase Inhibitors (TKIs). It focuses on correlating the dosages of these treatments with TKI dosages to ensure effective treatment adherence. If patients show unsatisfactory results, pharmaceutical interventions may be implemented, including changes in treatments or dosages. The study seeks to improve patient outcomes by optimizing treatment regimens based on individual responses.
Who should consider this trial
Good fit: Ideal candidates are adult patients diagnosed with Chronic Myeloid Leukemia who are currently taking a Tyrosine Kinase Inhibitor.
Not a fit: Patients who are legally incapacitated, unable to read or write in French, or those taking Ponatinib may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment effectiveness and adherence for patients with Chronic Myeloid Leukemia.
How similar studies have performed: Other studies have shown promising results in optimizing treatment regimens for CML, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient; * Patient affiliated to a social security scheme; * Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor (Imatinib, Nilotinib, Dasatinib, or Bosutinib); * Molecular response \< 4,5 Log; Exclusion Criteria: * Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity; * Not able to read and/or to write French; * Patient taking Ponatinib.
Where this trial is running
Saint-Etienne
- CHU de Saint-Etienne — Saint-Etienne, France (Recruiting)
Study contacts
- Principal investigator: Xavier SIMOENS, MD, PhD — CHU de Saint-Etienne
- Study coordinator: Elisabeth DAGUENET, doctor of science
- Email: elisabeth.daguenet@chu-st-etienne.fr
- Phone: 0477822875
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.